» Articles » PMID: 35586622

Fasting Serum IGFBP-1 As a Marker of Insulin Resistance in Diverse School Age Groups

Abstract

Introduction: The known markers of insulin resistance in obese children are well studied. However, they require serial measurements and complicated calculations. The objective is to study IGFBP-1 and its relation with other known risk measures.

Materials And Methods: The study included 98 New York City school students of diverse ethnic/racial backgrounds (57 males and 41 females), 11-15 years of age. Subjects were enrolled in a cross-sectional study, and anthropometric measures were collected. They underwent fasting intravenous glucose tolerance tests (IVGTT), and glucose, insulin, lipids, IGFBP-1, adiponectin and inflammatory markers were collected.

Results: The subjects were stratified into 3 groups based upon the BMI Z-score. Out of all the subjects, 65.3% were in the group with a BMI Z-score <1 SDS, 16.3% subjects were in the group with a BMI Z-score of 1 to 2 SDS, and 18.4% of the subjects were in the group with a BMI Z-score of more than 2 SDS. The group with a BMI Z-score of more than 2 SDS had increased waist circumference (WC), body fat, increased fasting insulin, and triglycerides (TG). This group had decreased levels of adiponectin and HDL and low IGFBP-1 as compared to the group with BMI <1 SDS. The group with a BMI Z-score of 1 to 2 SDS had a decreased level of IGFBP-1 as compared to the group with a BMI Z-score less than 1 SDS. IGFBP-1 inversely correlated with age, WC, BMI, body fat, TG, and insulin levels. IGFBP-1 positively correlated with adiponectin and HDL levels.

Conclusion: IGFBP-1 in children can identify the presence of insulin resistance in the group with BMI 1 to 2 SDS, even before the known markers of insulin resistance such as elevated triglycerides and even before decreased HDL and adiponectin levels are identified.

Citing Articles

Insulin-like Growth Factor-Binding Protein-1 (IGFBP-1) as a Biomarker of Cardiovascular Disease.

Lewitt M, Boyd G Biomolecules. 2024; 14(11).

PMID: 39595651 PMC: 11592324. DOI: 10.3390/biom14111475.


Insulin-like growth factor binding protein-1 and insulin in polycystic ovary syndrome: a systematic review and meta-analysis.

Jin Y, Sun F, Yang A, Yu X, Li Y, Liang S Front Endocrinol (Lausanne). 2024; 14:1279717.

PMID: 38174331 PMC: 10762309. DOI: 10.3389/fendo.2023.1279717.

References
1.
Heald A, Cruickshank J, Riste L, Cade J, Anderson S, Greenhalgh A . Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001; 44(3):333-9. DOI: 10.1007/s001250051623. View

2.
Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Takayama S . Low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Lipids Health Dis. 2010; 9:138. PMC: 3014951. DOI: 10.1186/1476-511X-9-138. View

3.
Kvaerner A, Hang D, Giovannucci E, Willett W, Chan A, Song M . Trajectories of body fatness from age 5 to 60 y and plasma biomarker concentrations of the insulin-insulin-like growth factor system. Am J Clin Nutr. 2018; 108(2):388-397. PMC: 6669326. DOI: 10.1093/ajcn/nqy103. View

4.
Tomizawa M, Kumar A, Perrot V, Nakae J, Accili D, Rechler M . Insulin inhibits the activation of transcription by a C-terminal fragment of the forkhead transcription factor FKHR. A mechanism for insulin inhibition of insulin-like growth factor-binding protein-1 transcription. J Biol Chem. 2000; 275(10):7289-95. DOI: 10.1074/jbc.275.10.7289. View

5.
Tworoger S, Mantzoros C, Hankinson S . Relationship of plasma adiponectin with sex hormone and insulin-like growth factor levels. Obesity (Silver Spring). 2007; 15(9):2217-24. DOI: 10.1038/oby.2007.263. View